Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Celgene Corporation : to Announce Third Quarter 2017 Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 10:25am CEST

Release date- 03102017 -

SUMMIT, N.J. - Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results.

The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Forward Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contact:

Tel: 908-673-9969

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
09/20CELGENE : Researchers at Celgene Report New Data on Thalidomide Analogs (In Vivo..
AQ
09/20CELGENE : New Breast Cancer Study Results Reported from Celgene (Synthetic Letha..
AQ
09/20ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Navicixi..
DJ
09/17CELGENE CORPORATION : - OTEZLA Showed Meaningful Improvements in Clinical and Qu..
AQ
09/13EVOTEC : And Celgene Enter Partnership In The Field Of Targeted Protein Degradat..
AQ
09/12CELGENE : OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Qu..
BU
09/11EVOTEC : and Celgene enter partnership in the field of targeted protein degradat..
AQ
09/08EVOTEC : Evotech And Celgene Enter Partnership In The Field Of Targeted Protein ..
AQ
09/06CELGENE : Findings from Celgene Provides New Data on Breast Cancer [Trial-level ..
AQ
09/04TODAY'S RESEARCH REPORTS ON TRENDING : Amarin and Celgene
AC
More news
News from SeekingAlpha
09/22Amazon Competitor Gets $300M At $1.2B Valuation 
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
09/20Celgene backs away from OncoMed's navicixizumab 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/18Celgene Yields The Most 
Financials ($)
Sales 2018 15 133 M
EBIT 2018 8 428 M
Net income 2018 4 591 M
Debt 2018 13 270 M
Yield 2018 -
P/E ratio 2018 14,05
P/E ratio 2019 10,48
EV / Sales 2018 4,95x
EV / Sales 2019 4,07x
Capitalization 61 699 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-15.39%61 699
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092